Dianthus Therapeutics Inc. (DNTH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.17B
Last updated: Nov 17, 2026 at 11:03 AM ET
Dianthus Therapeutics Inc. (DNTH) Stock Forecast
Analysts expect Dianthus Therapeutics (DNTH) to earn -$3.60 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.79M. Of 18 analysts, 18 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 1.94, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 5.6% |
| Buy | 17 | 94.4% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 22.6%.
- Fiscal year ending Dec 31, 2026
- -$3.60
- EPS consensus, revenue $2.79M
- Fiscal year ending Dec 31, 2027
- -$4.35
- EPS consensus, revenue $2.16M
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.60 | -$3.77 to -$3.46 | 8 | $2.79M | $2.40M to $3.64M | 11 |
| Dec 31, 2027 | -$4.35 | -$5.36 to -$3.47 | 11 | $2.16M | N/A | 14 |
Quarterly Estimates
The EPS consensus falls from -$0.98 for the quarter ending Dec 31, 2026 to -$1.03 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.98 | -$1.06 to -$0.88 | 17 | $445822 | N/A | 17 |
| Mar 31, 2027 | -$1.03 | -$1.12 to -$0.93 | 7 | $460280 | N/A | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.92.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.60 | -$3.81 | -$3.81 | -$3.83 | -$3.92 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.35 | -$4.61 | -$4.61 | -$4.62 | -$4.74 | N/A |
| Quarter ending Mar 31, 2027 | -$1.03 | -$1.09 | -$1.09 | -$1.10 | -$1.10 | N/A |
Frequently Asked Questions About DNTH
What is the DNTH stock forecast?
Consensus analyst estimates put Dianthus Therapeutics's EPS at -$3.60 for the fiscal year ending Dec 31, 2026, on revenue of $2.79M. The consensus rating from 18 analysts is Buy.
How do analysts rate DNTH stock?
Of 18 analysts covering Dianthus Therapeutics, 1 rates it Strong Buy, 17 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DNTH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.60, with estimates from -$3.77 to -$3.46 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.35, with estimates from -$5.36 to -$3.47 from 11 analysts.
What revenue do analysts expect from Dianthus Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.79M, with estimates from $2.40M to $3.64M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.16M.
How many analysts cover DNTH?
18 analysts rate Dianthus Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DNTH pages: Overview, Earnings, Forecast, Financials, Competitors